Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of a Protease Inhibitor for Treatment of HIV
News Nov 10, 2009
Concert Pharmaceuticals, Inc. announced that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection.
In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company’s strategic alliance with GlaxoSmithKline. The Phase 1b study will be used to assess the ability of CTP-518 to maintain acceptable therapeutic blood concentrations without a boosting agent such as ritonavir. It will also be used to determine doses for subsequent studies in HIV-infected patients.
“Preclinical data suggest that CTP-518 has the potential to be administered without pharmacokinetic boosting,” said Roger Tung, Ph.D., President and CEO of Concert Pharmaceuticals. “Ritonavir co-administration is currently recommended for all marketed HIV protease inhibitors. Our goal is to provide patients with a potent and well-tolerated once-daily therapy without the side effects, inconvenience and expense of an additional drug.”
The initial Phase 1 clinical trial is designed to evaluate the safety, tolerability and pharmacokinetics of CTP-518 in healthy volunteers after single and multiple doses. In addition, the Phase 1 study is intended to establish the pharmacokinetic enhancing effect of deuterium incorporation in CTP-518, and to determine whether CTP-518 dosed once-daily can maintain blood levels expected to be sufficient to suppress HIV replication when used as part of a standard three drug combination regimen.
The current standard of care is to co-administer all HIV protease inhibitors with ritonavir, except in patients who cannot tolerate ritonavir. The multiple ascending dose phase is a randomized, double-blind, placebo-controlled study in which study participants will receive CTP-518 or placebo for 14 days.
In June 2009, Concert and GlaxoSmithKline announced a potential $1 billion strategic alliance to develop three deuterium-containing medicines, including CTP-518. Concert has responsibility for research and development activities of CTP-518 through completion of Phase I studies. After the completion of the Phase I program, GSK may elect to obtain an exclusive, worldwide license to CTP-518. At such time, GSK would assume responsibility for development and commercialization.
Methane Hydrate Formation Studied Using Novel MicroreactorNews
Researchers at the NYU Tandon School of Engineering are using a novel means of studying how methane and water form methane hydrate that allows them to examine discrete steps in the process faster and more efficiently.READ MORE
University of Huddersfield Honorary Award Goes to RSC’s First Woman PresidentNews
The first woman President of the Royal Society of Chemistry, Professor Lesley Yellowlees, will collect an honorary award from University of Huddersfield, which will be presented at the University’s November Award Ceremonies.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE